Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.
Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.